Skip to content

Effect of Carum Carvi on Thyroid Hormones and TSH Level

Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls.

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01471288
Enrollment
40
Registered
2011-11-15
Start date
2011-05-31
Completion date
Unknown
Last updated
2011-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer Patients

Keywords

well differentiated thyroid cancer, Carum Carvi, Normal controls

Brief summary

Carum Carvi has been frequently used in traditional medicine for a variety of disease ranging from dyspepsia to Alzheimer's disease.We observed high TSH levels in few patients with thyroid cancer who receiving Carum Carvi despite being on suppressive dose of levothyroxin. TSH level returned to normal after discontinuation of the Carum carvi. This observation led to a pilot study for evaluation of the effect of carum carvi on thyroid function.

Interventions

DRUGCarum Cravi

40mg/kg of body weight

DRUGPlacebo

Placebo

Sponsors

Pharmaceutical Research Center
CollaboratorUNKNOWN
Mashhad University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-65 * Hypothyroid patients under treatment with levothyroxin * Normal euthyroid patients with no goiter

Exclusion criteria

* Pregnancy or lactation * Severe lung or gasterointestinal disease * Heart failure or renal failure

Design outcomes

Primary

MeasureTime frameDescription
Change of Thyroid and thyrotropin values from baseline at 2 and 6 weeks0-2-6 WeeksTSH, Free T4, Free T3, T4RIA and T3RIA

Secondary

MeasureTime frameDescription
Change of hypothyroidism index from baseline at 2 and 6 weeks0,2 and 6 weeksHypothyroidism Index

Countries

Iran

Contacts

Primary ContactSeyed Rasoul Zakavi, MD,IBNM
zakavir@mums.ac.ir+98-511-8022729
Backup ContactZohre Mousavi, MD, IBE
+98-8599359

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026